Page last updated: 2024-11-10

4,6-cholestadien-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3034666
CHEMBL ID68121
CHEBI ID157665
SCHEMBL ID1176920
MeSH IDM0095962

Synonyms (16)

Synonym
566-93-8
cholesta-4,6-dien-3-one
4,6-cholestadien-3-one
LMST01010059
4,6-cholestadienone
CHEBI:157665
cholest-4,6-dien-3-one
CHEMBL68121
cholesta-4,6-diene-3-one
nsc 119073
einecs 209-299-4
SCHEMBL1176920
4,6-cholestadiene-3-one
XIWMRKFKSRYSIJ-GYKMGIIDSA-N
AKOS027383675
DTXSID10862212
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
cholestanoidAny steroid based on a cholestane skeleton and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID108710Compound was evaluated for its potency in CDF1 mice and the abdominal fat weight was determined.1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID7636Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID7634Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID110288Evaluated for potency in CDF1 mice and the inhibition of body weight gain was determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID7635Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID113559Evaluated for potency in CDF1 mice and the ability of it to decrease feed consumption was determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID226241Feed efficiency was calculated by dividing body weight gain by feed consumption in mouse1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (30.00)18.7374
1990's2 (20.00)18.2507
2000's4 (40.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]